Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

DISEASE CHARACTERISTICS:

• Histologically confirmed non-small cell lung cancer
• No squamous cell carcinoma
• No histology in close proximity to a major vessel
• Resectable stage IB-IIIA disease
• No CNS or brain metastases

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 8.0 g/dL
• Bilirubin normal
• Creatinine ≤ 1.5 mg/dL
• Urine protein:creatinine < 1.0
• Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria:
• AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)
• AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN
• AP ≤ 5 times ULN AND AST and ALT normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment
• Adequate pulmonary and cardiovascular function to tolerate surgical resection
• No cavitation or history of hemoptysis (i.e., bright red blood ≥ ½ teaspoon)
• No existing peripheral neuropathy ≥ grade 1
• No known history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
• No history of serious systemic disease, including any of the following:
• Myocardial infarction within the past 6 months
• Uncontrolled hypertension (i.e., blood pressure > 150/110 mm Hg on medication)
• Unstable angina
• New York Heart Association class II-IV congestive heart failure
• Unstable symptomatic arrhythmia requiring medication
• Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are eligible
• Clinically significant peripheral vascular disease (i.e., grade II or higher)
• No history of significant neurological or psychiatric condition
• No known active infection within the past 14 days
• No serious, nonhealing wound, ulcer, or bone fracture
• No evidence of bleeding diathesis or coagulopathy
• No stroke within the past 6 months
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
• No other serious illness or medical condition
• No active infection
• No other currently active malignancy except nonmelanoma skin cancer
• Malignancies for which therapy has been completed and are considered to have ≤ 30% chance of risk of relapse are not considered active

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy or VEGF inhibitor
• No prior (i.e., within the past 4 weeks), concurrent, or anticipated participation in another experimental drug study except a Genentech-sponsored bevacizumab cancer study
• No major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days
• No anticipation for major surgical procedure during study treatment
• No fine-needle aspiration or core biopsy within 7 days prior to study entry
• No concurrent full-dose anticoagulation
• No other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy for this cancer